3M CO (MMM) Q3 FY2026: Net Income Surges 64.6% as Nonoperating Results Improve
3M CO (MMM) Q3 FY2026: "Net Income Surges 64.6% as Nonoperating Results Improve"
Introduction
3M's third-quarter FY2026 sales increased 1.0% year over year, while net income attributable to common shareholders surged 64.6%. Operating income grew 7.7%, with nonoperating results and tax changes contributing substantially to the net income improvement. Meanwhile, debt increased 19.0% from year-end, making repayment obligations important alongside earnings growth. The filing includes the complete balance sheet, cash flow statement and supporting notes, allowing equity and cash flows to be verified.
LineVest News | MinJeKim
Source: 3M's Q3 FY2026 Form 10-Q, filed October 20, 2026: income statement, page 3; balance sheet, page 5; cash flow statement, page 6; and accompanying notes. Amounts are presented in millions of U.S. dollars, the filing's original units, without currency conversion.
1. Consolidated Balance Sheet Analysis
1-1. Comparison of Major Asset Items
The prior date is December 31, 2025, and the current date is September 30, 2026. The comparison below is not quarter over quarter.
| Item | Prior (USD millions) | Current (USD millions) | Change | Interpretation |
|---|---|---|---|---|
| Cash and cash equivalents | 5,235 | 4,835 | -7.6% | Less immediately available cash |
| Accounts receivable | 3,533 | 4,116 | +16.5% | More sales proceeds awaiting collection |
| Inventories | 3,661 | 4,081 | +11.5% | More funds tied up in inventory |
| Property, plant and equipment | 7,101 | 6,969 | -1.9% | Lower net carrying value of factories and equipment |
| Intangible assets | 1,103 | 2,052 | +86.0% | Higher balances of assets such as patents and customer relationships |
Cash decreased by 400. Including current marketable securities, the balance fell 13.3%, from 5,933 to 5,145. The decline in liquid assets alongside rising debt makes the uses of cash important.
Accounts receivable and inventories increased by 583 and 420, respectively. Both grew faster than the 1.6% increase in January–September sales. However, comparing year-end balances with September balances can introduce seasonality. Note 3 discloses the Madison acquisition, but does not separately identify acquired receivables and inventories within its current and other assets. These balances alone do not establish weak sales or delayed collections.
The decrease in property, plant and equipment reflects the combined effects of depreciation, disposals, new investment and other changes. Net carrying value alone does not establish that capital spending was reduced. Goodwill, a separate item from intangible assets, also increased 14.4%, from 6,419 to 7,344. Goodwill represents the portion of an acquisition's consideration exceeding identifiable net asset value. Notes 3 and 4 identify 982 of acquired goodwill and 1,037 of finite-lived intangible assets from Madison; translation and other changes reduced goodwill by 57. Expected amortization of acquired amortizable intangible assets is 40 for the remainder of 2026 and 142 for 2027. These amortization amounts do not apply to goodwill.
1-2. Liability Structure — Financial Debt vs Operating Liabilities
Identifiable borrowings increased 19.0%, from 12,602 to 14,997. Short-term borrowings and the current portion of long-term debt increased from 1,670 to 2,439. Long-term debt increased from 10,932 to 12,558. No separate finance lease liability amount is provided, so none has been added to this total.
Among operating liabilities, accounts payable increased 12.5%, from 2,702 to 3,040. These represent unpaid purchases from suppliers. Accrued payroll decreased 13.8%, from 718 to 619. Other current liabilities increased 29.7% to 5,770, while other noncurrent liabilities decreased 21.5% to 8,499. The notes disclose components of these balances: PFAS-related environmental liabilities classified as current increased from approximately 700 to 2,800, while their noncurrent portion decreased from approximately 7,000 to 4,700. These changes help explain the shift toward current liabilities, although the entire movement cannot be treated as a reclassification or classified wholly as operating liabilities.
The current ratio declined from 170.8% to 140.8%. It divides current assets—assets generally expected to be realized, sold or consumed within one year or the operating cycle—by current liabilities. The decline indicates a smaller cushion for short-term obligations, but does not by itself establish a liquidity crisis.
1-3. Equity Structure
The balance sheet reports common stock of 9 at both dates, additional paid-in capital increasing from 7,440 to 7,566, and retained earnings increasing from 38,258 to 39,587. Thus, common stock plus additional paid-in capital increased from 7,449 to 7,575, while accumulated earnings remained substantially larger.
Total assets less total liabilities increased from 4,747 to 5,140. However, the current balance includes 971 of redeemable noncontrolling interest, presented outside permanent equity. Total equity actually decreased from 4,747 to 4,169, and equity attributable to 3M shareholders decreased from 4,702 to 4,127. Retained earnings increased, but the treasury stock deduction grew from 35,936 to 38,052. Note 8 provides the dividend, share repurchase and other equity movements needed to assess this change.
2. Consolidated Income Statement Analysis
2-1. Comparison of Key Earnings Measures
The prior period is July–September 2025, and the current period is July–September 2026. Net income is attributable to 3M common shareholders.
| Item | Prior (USD millions) | Current (USD millions) | Change |
|---|---|---|---|
| Sales | 6,517 | 6,584 | +1.0% |
| Operating income | 1,447 | 1,558 | +7.7% |
| Operating margin (%) | 22.2 | 23.7 | +1.5 pp |
| Net income | 834 | 1,373 | +64.6% |
| Net margin (%) | 12.8 | 20.9 | +8.1 pp |
Margin changes are expressed in percentage points (pp), the difference between percentages.
Sales increased by 67 and operating expenses decreased by 44, producing an increase of 111 in operating income. In particular, the prior-year quarter's business divestiture loss of 161 did not recur. This offset increases of 101 in selling, general and administrative expenses, 7 in research and development expenses, and 9 in cost of sales. This is why productivity improvements alone cannot explain the higher operating margin.
Changes in nonoperating results contributed more to the surge in net income. Other expense (income), net, moved from a net expense of 300 to net income of 112, improving pretax income by 412. Note 6 identifies a 375 improvement from changes in the value of 3M's retained Solventum investment, as a loss of 94 became a gain of 281. This investment remeasurement gain does not establish a recurring source of operating earnings.
Income tax expense also decreased from 308 to 261. Dividing the rounded income statement amounts gives a tax-to-pretax-income ratio of approximately 26.9% previously and 15.6% currently. Note 9 reports effective tax rates of 26.8% and 15.7%, respectively, and attributes the decline primarily to the tax effects of the retained Solventum investment and net costs of significant litigation. Lower taxes also lifted net income, but these factors do not establish that the lower rate will persist.
2-2. Fixed Costs vs Variable Costs
Fixed costs do not change substantially in the short term when production volumes change. Variable costs move with production or sales volumes. The income statement presents expenses by function, such as cost of sales, selling, general and administrative expenses, and research and development expenses. The filing also discloses depreciation and amortization and certain compensation costs, but does not provide a complete breakdown separating fixed and variable costs.
Cost of sales declined from 58.2% to 57.7% of sales. Meanwhile, selling, general and administrative expenses increased 12.3%, outpacing sales growth. Research and development expenses increased 2.4% to 304, representing 4.6% of sales.
Fixed-cost leverage occurs when rising sales spread fixed costs over a larger revenue base, allowing profit to grow faster. This quarter, the absence of the prior-year divestiture loss contributed substantially to the operating income improvement. The evidence is therefore insufficient to conclude that fixed-cost leverage strengthened.
3. Cash Flow Statement Analysis
Cash flows should be compared for January–September 2025 and 2026. The cash flow statement appears on page 6 of the filing.
| Item | Prior (USD millions) | Current (USD millions) | Change (USD millions) |
|---|---|---|---|
| Operating cash flow | 723 | 2,046 | +1,323 |
| Investing cash flow | 1,755 | -2,512 | -4,267 |
| Financing cash flow | -3,399 | 25 | +3,424 |
| Period-end cash and cash equivalents | 4,671 | 4,835 | +164 |
Current period-end cash is also confirmed by the balance sheet. Year-end 2025 cash of 5,235 is not the prior-year September balance and therefore cannot serve as the comparative figure in this table.
Income tax expense of 665 is the January–September income statement amount and may differ from cash taxes paid. The increase in the debt balance likewise does not separately show new borrowing and repayments. Free cash flow is operating cash flow less capital expenditure. Using the reported cash flow figures, this calculation gives 1,342 for 2026 (2,046 minus 704), compared with 61 for 2025 (723 minus 662). Operating cash flow improved, but management attributes the increase primarily to lower net payments for PFAS-related environmental liabilities and the Combat Arms Earplugs settlement, including the effect of insurance recoveries; net income growth alone does not explain it.
4. Additional Analysis This Report Must Address
① Quarterly versus year-to-date performance. January–September sales increased 1.6% to 19,114, and operating income increased 2.8% to 3,939. Net income attributable to common shareholders increased 10.7% to 2,959. The third-quarter net income growth rate should not be extrapolated into an annual growth rate.
② Timing of business divestiture losses. Although there was no third-quarter divestiture loss, the January–September loss was 343, exceeding 164 in the prior-year period. The quarterly improvement should be distinguished from the year's business restructuring burden.
③ Environmental and litigation uncertainty. Note 15 discusses litigation and settlements involving per- and polyfluoroalkyl substances, or PFAS, and provides settlement amounts, accrued liabilities and payment schedules. The public water supplier settlement requires total payments of 10,500–12,500, scheduled from 2024 through 2036. Recorded PFAS-related environmental liabilities were approximately 7,500 at September 30, 2026, including approximately 2,800 classified as current; 3M could not estimate possible losses beyond accrued amounts. Related expenses and cash payments can occur at different times, so their effects on earnings and liquidity must be considered separately.
④ Subsequent costs of expanded intangible assets. Whether the increase in intangible assets generates future sales and earnings matters. Finite-lived intangible assets are expensed over their useful lives. Lower expected returns can also lead to impairment charges that reduce asset values, although the current information does not establish whether such charges will occur.
5. Key Implications and Outlook
3M improved operating income and net income alongside modest sales growth. However, improved nonoperating results and a lower tax rate contributed substantially to net income growth. The pace of growth in the underlying business differs from the growth rate of bottom-line earnings.
The optimistic scenario is continued improvement in the cost-of-sales ratio and conversion of the increased receivables and inventories into cash. Conversely, nonrecurring investment remeasurement gains could slow earnings growth if they do not repeat, while persistent working-capital demands could weaken liquidity despite higher earnings. With debt rising and cash falling, the improvement in operating cash flow must be weighed against acquisition spending, shareholder distributions and scheduled litigation payments disclosed in the cash flow statement and notes.
Disclaimer
This report is based on 3M's Form 10-Q filed with the U.S. Securities and Exchange Commission (SEC) and is provided for informational purposes, not as an investment recommendation. It is not based on an annual report filed through DART.
